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Abstract Despite extensive efforts and continual progress
in research and medicine, outcomes for patients with high-
grade glioma remain exceptionally poor. Over the past
decade, research has revealed a great deal about the com-
plex biology behind glioma development, and has brought
to light some of the major barriers preventing successful
treatment. Glioblastoma multiforme (GBM) (stage 4
astrocytoma) is a highly dynamic tumour and one of the
most extreme examples of intratumoural heterogeneity,
making targeting with specific therapeutics an inefficient
and highly unpredictable goal. The cancer stem cell
hypothesis offers a new view on the possible mechanisms
dictating the heterogeneous nature of this disease and
contributes to our understanding of glioma resistance and
recurrence. Revealing cell division characteristics of initi-
ating cell populations within GBM may represent novel
treatment targets and/or the effective repurposing of
existing therapies. In this review, we discuss the potential
role of targeting the cyclin-dependent kinases (CDKs)
driving this specific population. We also describe devel-
opments using multi-omic approaches that may aid in
stratifying patient populations for CDK inhibitor therapy.
Key Points
Despite advances in understanding the initiation and
progression of glioblastoma multiforme, prognosis
remains poor.
Promising pre-clinical data targeting the cyclin-
dependent kinases (CDKs) have failed to yield
similar results in the clinic.
Advances in stratifying patient populations and in
CDK drug design offer new hope for this therapeutic
direction.
1 Overview
Glioblastoma multiforme (GBM) is one of the most
aggressive cancers and the most common adult primary
brain malignancy. Despite efforts to improve GBM sur-
vival, optimally treated patients achieve a median survival
of only 14 months, with a 26% 2-year survival rate [1, 2].
GBM presents with higher complexity than previously
thought, with tremendous intratumoural heterogeneity
comprising cells of distinct genetic, phenotypic and mor-
phological profiles. Among the heterogeneous cellular
mass, specific clones are able to evade therapy, leading to
cancer progression or relapse [3–7]. Imaging methods and
classical histopathological examination currently remain
the gold standard in glioma diagnostics [7]. Integration of
phenotypic and genotypic parameters in the World Health
Organization (WHO) classification has improved the
accuracy of diagnosis and prognosis for central nervous
system (CNS) tumours; however, these are seldom used to
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direct new therapy for GBM [8, 9]. Standard multimodal
therapy involves surgery and/or radiation with concurrent
chemotherapy using the alkylating agent temozolomide
(TMZ). Considering the disease heterogeneity and sub-
jective nature of the histological assessment, current
diagnostic and treatment approaches are clearly insufficient
to improve patient outcomes for GBM.
Dissecting the biological nature of brain tumour
heterogeneity truly began with the discovery of cancer
stem cells in the hematopoietic system [10]. While the
initial cell of origin remains a subject of debate, it is clear
that regardless of the original source, populations of cells
capable of self-renewal can exist, which can recapitulate
the heterogeneity of the parental tumour in a xenograft
model [11, 12]. These cells are often referred to as brain
tumour initiating cells (BTICs) to avoid the rigidity
imposed by the cancer stem cell hypothesis. Research
profiling the pathways and genes involved in the aggressive
behaviour of BTICs is offering new opportunities to
develop effective treatments targeting this aggressive cell
population [3–5]. This review will focus on the potential
utility of targeting unique cell cycle characteristics in this
population and will ask how to reliably predict the driving
pathways given the heterogeneous nature of GBM.
2 Current Glioblastoma Multiforme (GBM)
Classification
2.1 Genomic Classification of GBM
Recent efforts to characterize both low- and high-grade
gliomas have demonstrated that characterizing according to
molecular features may be more important than classical
histopathological-defined grading [13, 14]. In high-grade
glioma, the number of mutational events occurring is stag-
gering, and getting a handle on the hierarchy of these events
represents a significant hurdle. By sequencing 22,661 genes,
Parsons et al. established that on average over 45 different
mutations characterize a single GBM tumour [15]. Work
performed by the Cancer Genome Atlas Research Network
[16], involving 91 GBM samples, established that 223 genes
were affected by 453 non-silent somatic mutations [6]. The
detailed analysis of 601 genes revealed a mutational spec-
trum with noted aberrations in p53, retinoblastoma (Rb) and
tyrosine kinase pathways [16]. This has since been expanded
on to include exome sequencing of 291 glioblastomas, RNA
sequencing of 164 samples and copy number, DNA methy-
lation, protein, messenger RNA (mRNA) and microRNA
(miRNA) expression profiles of over 500 GBMs [17]. Using
genomic profiling to classify tumours at a molecular level is
one way to organize this chaos, and is quickly becoming an
indispensable tool in modern medicine. In a 2006 study,
based on the core gene expression as well as copy number
data from 107 samples, Phillips et al. determined three
molecular signatures defining prognostic subclasses of high-
grade glioma, designated proneural (PN), mesenchymal
(MES) and proliferative (PROLIF) [18]. Almost 90% of
grade III tumours belonged to the PN subtype, with this
group representing a younger population with a better
prognosis. GBM on the other hand could be classified into
each of the three subclasses. In a later advance of this work,
Verhaak and colleagues further classified GBM into four
subtypes using a 840-gene signature [6]. In this work, PN and
MES subtypes overlapped with previously identified popu-
lations; however, the PROLIF group was further subdivided
into a classical and neural signature. Multiple efforts have
followed to establish alternative categorization; however,
themutual exclusivity of PN andMES subtypes continued to
emerge as a robust signature. The magnitude of the differ-
ences between these subtypes suggests separate disease
entities, potentially due to a distinct cell of origin.
Interestingly, the defined genomic subtypes parallel
stages in forebrain neural development and expression of
tissue specific markers, suggesting that processes driving
glioma progression resemble those of neurogenesis [18].
The PN subtype tends to associate with secondary GBM
and is characterized by markers of normal brain and neu-
rogenesis. Whereas the more aggressive GBM subtypes,
PROLIF and MES, express genes indicative of cell pro-
liferation, angiogenesis and wound healing, signatures
indicative of poor prognosis in epithelial tumour types [18].
Ample literature suggests that the PN subtype is driven by
an early mutation of TP53, regulating consistent genetic
changes through tumour progression [19–21], whereas
complex aberrations in multiple molecular pathways seem
to underlie the MES subtype [21–26]. Hence, genomic
subtyping of high-grade glioma has provided a prognostic
classification scheme as well as the beginnings of a net-
work of processes that may drive these specific forms of
GBM to initiate and progress. This advance in classifying
GBM has contributed to a better understanding of GBM
pathology and offers significant potential for the advance
of therapeutic strategies; however, a genomic classification
approach alone is restricted in its ability to predict the
actual response of a tumour to treatment. This is due in part
to the extreme heterogeneity of the disease and the
knowledge that individual cases of GBM comprise indi-
vidual subclones belonging to these GBM subtypes [9], as
we will discuss.
2.2 Proteomic/Phosphoproteomic Classification
of GBM
The availability of proteomic signatures and protein
biomarkers determined in tumour biopsies, plasma or
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bodily fluids throughout the treatment course has enormous
prognostic potential and ideally can aid in treatment deci-
sions. Approaches comparing protein expression patterns
of brain tumours to normal matching tissue allows for
assessment of potential disease biomarkers with clinical
utility. Proteomic profiling includes not only large scale
analysis of protein expression, but also assessment of the
interactome and post-translational modifications. In a
recent study Wei et al. utilized a quantitative and multiplex
single-cell barcode chip method [27] to perform phospho-
proteomic analysis in vivo in a patient-derived GBM model
of resistance [28]. The authors showed that in response to
treatment, cells failed to undergo changes that would
support genetic selection, but rather rapidly re-wired pro-
tein signalling pathways as a dominant mechanism of
resistance. This study provides solid evidence that a multi-
omics approach is essential for molecular assessment of
tumour resistance and is necessary for subsequent predicted
on-target intervention to arrest tumour growth in vivo. This
study also revealed that the timing of analysis may be
critical, where deep genetic changes may occur upon long-
term exposure to therapy and drive selection of treatment
resistant cell populations, while rapid adaptation develops
through proteins and their phosphorylation networks.
3 Detecting Brain Tumour Initiating Cells
(BTICs) Using Multi-omic Approaches
Extensive investigation employing genomic subtyping is
crucial to determine whether we can accurately classify the
characteristics of cancers that can arise from select BTICs
to guide therapeutic decisions. The observed cellular
hierarchy in glioma resembles hierarchy of normal brain
development and homeostasis, suggesting that ontogeny is
reflected in cancer [29]. The complicated nature of brain
tumours is mimicked after brain complexity, with cellular
dynamics regulated by the niche and responsive to
microenvironment maintenance cues [30]. Unlike normal
brain tissue where generation of subsequent committed cell
populations is a stage-specific and clearly defined process,
in glioma, distinguishing the dynamics between self-re-
newing BTICs at the top of the hierarchy and their pro-
genitor populations is still a work in progress.
Phillips et al. established clear genomic parallels
between brain tumourigenesis and forebrain neurogenic
development, giving insight and better understanding of the
character of possible glioma origin and disease evolution
and progression [18]. The established subtype model with
demonstrated differences in phosphatase and tensin
homologue (PTEN) status and Notch signalling supports
the notion that glioma aggressiveness relies on processes
that regulate cell fate choices during neurogenesis. The
speculated model of glioma initiation and progression
based on the determined genomic signatures suggests that
established subtypes arise from a common cell of origin,
but the MES subtype remains more stem-like, PROLIF
resembles a transit amplifying state, while the PN subtype
adopts a phenotype of committed neural precursors char-
acterized by low proliferation rates. The responsiveness of
both neural stem cells as well as transit amplifying cells to
epidermal growth factor (EGF) was established previously
[31]. Both MES and PROLIF subtypes are characterized by
amplification of epidermal growth factor receptor (EGFR)
and showed ability to propagate neurospheres in response
to EGF ? fibroblast growth factor (FGF)-containing
media, suggesting that established subclasses may repre-
sent distinct differentiation stages of glioma and that their
stem-like character can be predicted by genomic profiling.
4 BTICs in Drug Resistance
The therapy-mediated selection of resistant clones is sup-
ported by ample evidence in the literature [10, 29, 32–34],
and it relates to the cancer stem cell model of intratumoural
heterogeneity where cancer stem cells divide asymmetri-
cally to self-renew and create more differentiated progeny.
Due to environmental pressure induced by chemo- and/or
radiotherapy the heterogeneous mass is exposed to, the
most resistant clone survives and expands, leading to
relapse.
Extensive evidence suggests that glioma recurrence
truly relies on the stem-like BTIC population; however,
more investigation is required to establish whether a model
of selection, interconversion to a cancer stem cell model, or
their co-existence is at the source of glioma expansion after
treatment [35–38]. In opposition to the selection model, a
study involving long-term exposure to therapeutic con-
centrations of TMZ reported expansion of glioma stem cell
pools in cell lines, xenograft models and primary patient-
derived cultures, where these stem cell-like populations
were newly converted from non-cancer stem cell popula-
tions [37]. Demonstrated data reveal that observed inter-
conversion under TMZ influence leads to generation of
highly invasive and tumourigenic BTIC populations char-
acterized by expression of parental molecular markers. The
presented data argue against the selection model and sug-
gest that glioma stemness and subsequent relapse can rely
on cellular plasticity. Moreover, the induction of plasticity
by routinely used chemotherapeutic agents such as TMZ
brings in a question about the molecular mechanism and
spectrum of the observed interconversion, occurring per-
haps under different chemotherapy treatments. It is evident
that a better understanding of the genomic and cellular
dynamics behind glioma heterogeneity and application of
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the knowledge in preclinical and clinical studies is of high
importance to assure evasion of patient relapse and to
provide successful clinical outcomes.
5 Detecting BTICs During Drug Resistance
The extensive and multidimensional search for the glioma
cell of origin, as well as cell type triggering the disease
recurrence throughout the heterogeneous mass of the
tumour, recently adopted a single-cell analysis approach. A
group led by Dirks utilized single cell-derived clonal
analysis in efforts to establish a link between genomic and
functional heterogeneity [9]. They revealed genetic signa-
tures correlating with specific functional behaviour of
individual clones derived from a single tumour that
exhibited distinct proliferation, differentiation and
chemotherapy resistance characteristics. Importantly, the
study demonstrated that TMZ-resistant clones exist in an
untreated tumour ab initio, without the requirement for
TMZ-mediated selective pressure or induction of plasticity,
described earlier. A parallel study by Soeda et al., per-
formed on four clones obtained from an individual patient,
not only confirmed the functional diversity described by
Dirks, but managed to link more stem-like phenotypes to
enhanced invasiveness of the clones when xenografted to a
mouse model [39]. Although the analysed clones showed
differences upon surface marker profiling and diverse
responsiveness to EGFR inhibitors, the authors failed to
correlate the marker and drug sensitivity profile with clone
phenotypes in their sample size [39]. The novel findings
show that single glioma tumours contain multiple clones of
distinct response to therapeutic agents and suggest a novel
avenue of the individualized approach where clone-specific
therapy should be tested and developed for efficient glioma
treatment.
Using the single-cell analysis approach in a phospho-
proteomics study, Wei et al. reported no changes in stem-
ness marker gene expression between therapy responsive
and recurrent/resistant tumours [28]. This study argued that
acquired drug resistance was not mediated by expansion of
an aggressive BTIC pool. They presented evidence of an
adaptive mechanism of rapid modification of protein net-
works, supporting the importance of examining proteomics
at the source of glioma heterogeneity and recurrence.
Investigation into the phosphoproteome dynamics of
glioma-initiating cells upon EGF stimulation, using a
powerful combination of high resolution mass spectrome-
try and single isotope labelling of amino acids (SILAC),
demonstrated upregulation and downregulation of hun-
dreds of phosphorylation sites on proteins mainly respon-
sible for signal transduction and transcription as well as
changes in phosphorylation status on nestin and vimentin
stem cell markers and proteins involved in pathways reg-
ulating stemness [40]. The reported results suggest not only
the role of EGF in regulation of phosphoprotein network
re-wiring, but also point at potential analogous effects upon
treatment of glioma with EGFR antagonists, underscoring
the necessity of differential phosphoproteome profiling of
resistant BTICs.
6 Potential for the Novel Targeting of BTICs
Using Cyclin-Dependent Kinase Inhibitors
(CKIs)
6.1 CKI Drugs in GBM Treatment
A plethora of tumourigenic events in brain cancer drive
proliferation through the recruitment of cyclin-dependent
kinases (CDKs) in the G1 phase of the cell cycle. Fur-
thermore, the hallmark of genomic instability in GBM is
related to perturbations in the S phase and G2/M transition
controlled by CDKs. Understanding which CDKs are
activated in GBM and whether there are unique alterations
to these complexes that are utilized to override protective
cell cycle checkpoints is one approach that may provide
utility in battling brain tumours in a clinical setting. Pre-
clinical studies and clinical trials over the past two decades,
testing the effectiveness of CDK inhibitors (CKIs), have
generated mixed results, with a non-definite conclusion
with regard to the utility of these agents.
Initially developed CKIs were designed to exhibit a
broad spectrum of action against CDKs (pan-CKIs). The
most extensively studied first-generation agent, flavopiri-
dol, induces a cell cycle arrest in G1 and G2 phases
in vitro, causes significant cytotoxic effects due to inhibi-
tion of CDK7 and CDK9 in vivo, and demonstrates low
levels of clinical activity [41]. In a study by Hayashi et al.,
flavopiridol showed promising results in combination with
TMZ, as it enhanced cytotoxicity in a glioblastoma cell line
and sensitized xenografted mice to TMZ [42]. TMZ
resistance was acquired through stimulation of G2 check-
point-mediated DNA repair activity. Although, the pre-
sented data suggested that use of CKI suppressed the DNA
repair mechanisms at the G2/M transition and prevented
TMZ resistance, a study involving orthotopic xenograft
models is required to further evaluate the potential pre-
clinical efficacy of the proposed combination in glioma
therapy.
To increase the selectivity of the CKIs towards CDK1
and CDK2, several compounds were developed as second-
generation CKIs (Table 1). This generation of inhibitors
exhibited promising results in a pre-clinical setting; how-
ever, only a few were able to pass through phase I of
clinical trials. Dinaciclib, a potent inhibitor developed to
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specifically inhibit CDK1, CDK2, CDK5 and CDK9,
inhibits proliferation of human glioma cell lines indepen-
dent of p53 mutation status [43]. Combination of dinaciclib
with multiple conventional chemotherapeutic agents as
well as growth signalling inhibitors failed to induce cell
death. The synergistic apoptotic response was found when
dinaciclib was combined with Bcl-2/Bcl-xL inhibitors [43],
suggesting the importance of screening the effects of CKIs
in combination with different therapeutics to determine
their potency and seek molecular-based reasons for the
favourable response.
Highly selective CDK4/6 inhibitors, palbociclib and
abemaciclib, induce cell cycle blockage through inhibition
of Rb1 phosphorylation [44]. The cyclin D1-CDK4/6-Rb
pathway is altered in nearly 80% of human gliomas and is
one of the three most perturbed pathways [16, 17], sug-
gesting both inhibitors as promising agents in glioma
treatment. In in vivo studies, palbociclib and abemaciclib
demonstrated an advantage in combination with TMZ and
radiotherapy [44]. Importantly, both compounds have the
ability to cross the blood–brain barrier [44]. Investigation
into their anti-proliferative effects within a brain is war-
ranted. Abemaciclib has recently moved into phase I
clinical trials for several solid cancers, including glioblas-
toma [45].
6.2 Battling Weaknesses of CKI Specificity
The observed clinical failure of first-generation CKIs is
likely attributed to their low specificity, which is, in con-
sequence, followed by difficulty dissecting the actual
molecular response in vivo. The lack of specificity of this
generation of CKIs also complicates any efforts to stratify
the patient population, design effective combination
strategies, and modify the existing compound. Second-
generation inhibitors offer promise; however, one then
must consider the possible redundancies of other CDKs
and/or extreme lethality. Notably, knockouts of the G1/S
CDK, CDK2, despite having redundancy for normal
developmental programmes, demonstrate that CDK2 is
Table 1 Reported CKIs with antiglioma effects
CKI Targets BBB
penetration
Therapeutic effect against glioma Glioma
therapy
combination
tested
Glioma-
specific
clinical
trials
References
Roscovitine
(Seliciclib,
CYC202)
CDK5/p35; Cdc2/
Cyclin B; CDK2/
Cyclin E; CDK2/
Cyclin A
Yes Increased sensitivity to therapy induced
apoptosis in vitro
TRAIL Not
reported
[61–63]
Milciclib
(PHA-
848125)
CDK2/Cyclin A;
CDK7/Cyclin H;
CDK4/Cyclin D1
Yes Inhibition of cell proliferation,
downregulation of CDK4/Rb transduction
pathway markers; induction of cell death
through autophagy in vitro and in vivo
TMZ Not
reported
[64, 65]
SNS-032
(BMS-
387032)
CDK7/Cyclin H;
CDK2/Cyclin A;
CDK2/Cyclin E;
CDK9/Cyclin T
Not
reported
Inhibition of hypoxia induced U87MG cell
invasion, block of HIF11a-expression
in vitro
Not reported Not
reported
[66–68]
SCH727965
(dinaciclib)
CDK2; CDK5; CDK1;
CDK9
Not
reported
Induction of apoptosis in synergy with
ABT-737 or ABT-263, small-molecule
Bcl-2/Bcl-xL antagonists
ABT-737 Not
reported
[43, 69]
PD-0332991
(palbociclib)
CDK4/Cyclin D3;
CDK4/Cyclin D1;
CDK6/Cyclin D2;
CDK2/Cyclin E2
Yes In vitro G1 cell cycle arrest and induction of
senescence; suppression of GBM
xenograft growth in vivo
TMZ,
radiotherapy
Yes [70, 71]
PHA-767491 Cdc7; CDK9; CDK2 No Decreased cell proliferation and viability,
induction of apoptosis in vitro
Not reported Not
reported
[72, 73]
Purvalanol A Cdc2/Cyclin B;
CDK2/Cyclin E;
CDK2/Cyclin A;
CDK4/Cyclin D1
Yes Inhibition of GBM stem-like cells invasion
in vitro and in vivo
Not reported Not
reported
[74, 75]
LY2835219
(abemaciclib)
CDK4; CDK6 Yes Tumour xenograft growth suppression
in vivo
TMZ Yes [45, 76]
BBB blood–brain barrier, CDK cyclin-dependent kinase, CKI cyclin-dependent kinase inhibitor, GBM glioblastoma multiforme, TMZ temo-
zolomide, TRAIL tumour necrosis factor-related apoptosis-inducing ligand
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essential for transformation driven by several classical
oncogenes [46, 47].
6.3 Non-canonical Cyclin-Dependent Kinase
Activators
An interesting idea for an alternate mechanism of CDK
targeting is to target CDKs bound to non-canonical binding
partners [48]. Since current design of synthetic CKIs relies
on the CDK protein conformation bound to known
canonical cyclins, one can speculate that CDK non-cyclin
binding partners can continue to stimulate CDK activation
in the presence of synthetic CKI inhibition. One family of
Speedy/RINGO proteins has been well established as CDK
binding partners with no homology to cyclins [49]. All
mammalian Speedy/RINGO proteins demonstrate diverse
tissue expression, have been shown to bind CDKs in vivo,
and differ in specific CDK binding preferences. One family
member, Spy1A1 (gene SPDYA) has the capacity to bind to
both CDK2 and CDK1, and has a demonstrated role in
neural malignancies, including human GBM [50, 51].
Spy1A1 exhibits surprising differences in CDK activation
in that Spy1-bound CDKs are activated in the absence of
CDK-activating kinase (CAK)-mediated phosphorylation
on the T-loop (Thr-160/161) [48, 52]. Importantly,
Spy1A1-CDK complexes are less sensitive to the inhibitory
phosphorylation on Thr-14/Tyr-15 on the CDK, and are
also less susceptible to p21Cip1 cell cycle inhibitor action
[53]. Hence, the presence of Spy1A1 protein may perpet-
uate an active CDK in the face of senescence-inducing
stimuli—such as oncogenic mutations and DNA muta-
tions—presenting a very attractive target and potential
combination therapy with other cytotoxic approaches. Pre-
clinical data using patient-derived GBM suggest that this
may be a powerful approach to target the BTIC population
in human GBM [50]. Analogically, proteins p35 and p39,
lacking cyclin sequence homology, are essential binding
partners of CDK5. Moreover, p35 and p39 are found
exclusively in the brain [54, 55], which is consistent with
established roles of CDK5 in processes of neurogenesis,
neuronal maturation, neurodegeneration and brain cancer
[56–58]. CDK5 does not require phosphorylation on the
T-loop, and it becomes readily activated by binding to its
partner proteins [59]. Currently, there is no work done on
the potential importance of this family of proteins as a
therapeutic target and/or on the efficacy of current
approaches.
In summary, non-cyclin CDK activators constitute a
group of novel potential targets in designing therapies
directed against CDK activity in human glioma. Targeting
selected Speedy/RINGO proteins through abrogation of
CDK binding or specific inhibition of the complex may
improve the efficacy of standard and available synthetic
CKIs, as well as potentially enhance the specificity of the
treatment as a monotherapy or in combination with con-
ventional chemotherapy agents. Due to the brain tissue
specificity of the CDK5/p35/p39 complex, eradication of
binding between CDK5 and its known partner proteins can
contribute to development of therapies selectively directed
towards neural malignancies. As new proteins are being
discovered to drive CDK5 activity in different malignan-
cies [60], high-throughput screens of novel binding part-
ners of CDKs emerge as a new and important avenue in
seeking specific protein targets. Obtaining highly specific
and potent CKIs may advance success in glioma therapy.
7 Conclusion
High-grade gliomas remain among the most challenging
malignancies to treat, and patient outcomes continue to be
very poor. Advances in technology have revolutionized
our understanding of glioma biology, revealing the true
complexity and dynamics of brain tumour heterogeneity.
The discovery of stem-like populations of cells in brain
cancer has become a central axis integrating glioma
research. Attempts to address critical questions on cancer
stem cell characteristics and their role in glioma therapy
resistance and recurrence stimulated a new era of single-
cell analysis, including genomics, proteomics and their
link to functional heterogeneity. Ultimately, targeting the
driving population remains a key goal. New opportunities
for therapeutic intervention include synthetic second-/
third-generation targeted CKIs. To utilize these approa-
ches, researchers must determine how to integrate and
interpret information about cancer stem cell-driven
dynamics with steady-state tumour genomic, proteomic
and phosphoproteomic profiles. Ultimately, this would
require a global effort to combine many areas of expertise
and share resources and databases to fully utilize and
push the limits of existing technology. Implementing a
proper personalized, targeted approach such as this
requires this orchestrated effort to cascade down into the
clinic. While the technologies and ideas exist, funding
and organization of such a global effort is certainly a
futuristic ideal.
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